Hims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...

Hims & Hers Health (NYSE:HIMS) on Wednesday announced plans to expand in Canada next year with the loss of market exclusivity ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Danish pharmaceutical giant Novo Nordisk is set to lose Canadian patent protection on its popular semaglutide-based drugs, ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Hims & Hers cofounder and CEO Andrew Dudum dropped out of Forbes’ billionaire ranks on Monday – less than two months after joining the three-comma-club, in May. Dudum, 36, lost more than $400 ...

"We've leveraged our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1 injections available today," Hims & Hers Health CEO and co-founder Andrew Dudum said ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.

COPENHAGEN (Reuters) -Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs. The two companies had announced a collaboration in April ...